Bardia Askari, Ph.D.
* ***** ** *** #: 206-***-****
Garrison NY, 10524 Email: k8x6wr@r.postjobfree.com
I am a highly experienced and capable research pharmacologist with over 15 years of experience. My research interests have mainly focused on the effects of investigational, pre-clinical and clinical drugs in a variety of in vitro and in vivo settings. I have supervised teams of students, postdoctoral fellows and technicians in pursuit of these projects. I am an able and effective communicator.
Scientific Experience:
Project Coordinator 2010-2011
Division of Cardiology, University of Washington School of Medicine
Investigated, with a group of technicians and faculty, cardiac and renal functions in a mouse model of diet-induced obesity.
Assistant Professor (Acting) 2008-2010
Dept. of Pathology, University of Washington School of Medicine
• Investigating the effect of a novel PPAR-α agonist on the development of kidney disease in a newly characterized mouse model of diabetic nephropathy
• Explored the effect of MK 886, an inhibitor of 5-lipoxygenase activity on adiposity and atherosclerosis in a diet-induced model of type II diabetes
• Investigated the role of fatty acids on the renin-angiotensin-aldosterone system in immortalized mesangial cells
• Promoted and engaged in multiple collaborative projects
Instructor (Acting) 2004-2008
Dept. of Pathology, University of Washington School of Medicine
• Investigated the pharmacodynamic effects of thiazolidinediones and fatty acid analogues on fatty acid- processing enzymes.
• Provided laboratory guidance, troubleshooting skills and mentored provided guidance to a group of 10 graduate and undergraduate students, post-doctoral fellows and research staff
Research Associate 2003-2004
Howard Hughes Medical Institute, University of Washington School of Medicine
• Studied the biophysics of lipid membranes in macrophages
Senior Fellow
Dept. of Pathology, University of Washington School of Medicine 2000-2003
• Initiated studies centering on the effects of fatty acids on phosphoprotein signaling in primary cell cultures of vascular cells.
• Developed tools for researching cellular lipids homeostasis
• Identified and promoted academic collaborations
Graduate Student/Research Associate 1992-2000
Dept. of Pharmacology, New York Medical College
• Analyzed the effect of a novel thromboxane receptor antagonist (BMS180291) on salt and water balance in an ex vivo model of renal function (isolated, perfused kidney).
• Investigated the role of eicosanoids, inflammatory cytokines and the renin-angiotensin system in rat models of hypertension (i.e aortic coarctation, angiotensin II-infusion, 5/6 nephectomy, uninephectomy).
• Provided guidance and tutorial sessions for medical students in the area of cardiovascular pharmacology
Education:
New York Medical College, Valhalla, NY MSc, PhD., Pharmacology
State University of NY at Stony Brook, Stony Brook, NY BSc, Biology
Honors and Funding Support:
PRINCIPAL INVESTIGATOR
“Long Chain Fatty Acids and Mineralocorticoid Receptor Upregulation in a Mouse Model of Diabetic Nephropathy” $75,000/year
Agency: Mouse Metabolic Phenotyping Centers
Type: MMPC Initiative for Collaborative Research on the Mouse Dec 2009-Nov 2010
PRINCIPAL INVESTIGATOR
“The Role of Aldosterone in Macrophage Function in Diabetes-Accelerated Atherosclerosis”
Agency: Diabetes and Endocrinology Research Center $50,000/year
Type: Pilot and Feasibility Research Award June 2006-June 2008
SENIOR FELLOW
Ruth L. Kirchstein National Research Service Award 2000-2003
Dept. of Pathology, University of Washington School of Medicine
Invited Speaker:
“Renal Mitochondrial Dysfunction in a Mouse Model of Diabetic Nephropathy” Pathology Presents Seminar Series, Seattle, WA October 2010
"Effect of the inhibition of 5-lipoxygenase activating protein on adipose tissue macrophage content and atherosclerotic lesion formation in obese and diabetic mice” South Lake Union Group Seminar Series, Seattle, WA February 2010
“Involvement of Long Chain Fatty Acids in a Mouse Model of Diabetic Nephropathy” Research and Training Seminars, Diabetes and Obesity Centers of Excellence, Seattle, WA March 2009
“Fatty Acids and the Renal Complications of Type II Diabetes Mellitus” Cardiovascular Center Breakfast Club. Seattle, WA June 2008
“Do Long-Chain Acyl Co-A Synthetases Play a Role in Diabetic Nephropathy?” The Diabetes and Endocrinology Research Center/Clinical Nutrition Research Unit Annual Retreat. Seattle, WA December 2007
“Thiazolidinediones and Anti-inflammatory Prostanoids in the Artery Wall and the Kidney.” Department of Pathology Annual Retreat. Leavenworth, WA August 2007
“Aldosterone and Cardiovascular Disease: Past, Present and Future” Cardiovascular Center Breakfast Club. Seattle, WA May 2005
“The Role of Acyl Co-Enzyme A Synthetases in Lipid Uptake in Vascular Cells” Cardiovascular Center Breakfast Club. Seattle, WA June 2004
“Synergism between Fatty Acids and IGF-I in Smooth Muscle Cell Proliferation in Relation to Diabetes-Accelerated Atherosclerosis” Cardiovascular Center Breakfast Club. Seattle, WA January 2002
“Insulin-like Growth Factor-I Induced Proliferation in Arterial Smooth Muscle Cells: Role of Phospholipases”. Frontiers of Cardiovascular Research, Seattle, WA October 2001
PUBLICATIONS:
Wietecha T, Hudkins KL, Fox EJ, Loeb, LA, Alpers CE, Askari B. (2012) Effect of CP-900691 on the Development of Diabetic Nephropathy in the BTBR ob/ob mouse. (in preparation)
Rubinow KB, Nelson J, Mar D, Bomsztyk K, Askari B, Lai M, Smith KD, Han M, Davis RJ, Bornfeldt KE. (2012) Acyl-CoA Synthetase 1 is Induced by Gram-Negative Bacteria and LPS through p38α MAPK Activation in Macrophages. (in preperation)
Pichaiwong W, Hudkins KL, Wietecha T, Tachaudomdach C, Li W, Askari B, Kobayashi T, Johnson S, Rabinovitch P, Pippin JW, Shankland SJ, Alpers CE. (2012) Reversibility of Diabetic Nephropathy and Podocyte loss in the BTBR ob/ob mutant mouse. (in preparation)
Askari B, Goodspeed L, Wang S, Weitz K, Kim J, Haw III A, Han CY, O’Brien KD, Chait A (2012) Paradoxical Effects of MK-886, a 5-lipoxygenase activating protein inhibitor, on adipose tissue macrophage content and atherosclerosis in a mouse model of type 2 diabetes. (in preparation)
Golej DL, Askari B, Kramer F, Barnhart S, Vivekanandan-Giri A, Pennathur S, Bornfeldt KE. (2011) Long-chain acyl-CoA synthetase 4 modulates prostaglandin E2 release from human arterial smooth muscle cells. Journal of Lipid Research 52(4): 782-93
Alpers CE, Pichaiwon W, Wietecha T, Kowaleska J, Banas MC, Spencer MW, Pippin JW, Shankland J, Askari B, Rabaglia ME, Keller MP, Attie AD, Hudkins KL. (2010) A New Mouse Model of Progressive Diabetic Nephropathy. Journal of the American Society of Nephrology 21(9): 1533-1542
Zhu WZ, Xie Y, White KN, Askari B, Laflamme MA. (2010) Neuregulin/ErbB Signaling Regulates Cardiac Subtype Specification in Differentiating Human Embryonic Stem Cells. Circulation Research 107(6): 776-86
Ware, CB, Wang L, Mecham BH, Shen L, Nelson AM, Bar M, Lamba DA, Dauphin DS, Buckingham B, Askari B, Lim R, Tewari MD, Gartler SM, Issa JP, Pavlidis P, Duan S, Blau CA. (2009) Histone Deacetylase Inhibition Elicits an Evolutionarily Conserved Self-Renewal Program in Embryonic Stem Cells. Cell-Stem Cell 4(4): 359-369
Askari B, Kanter JE, Sherrid AM, Golej DL, Bender AT, Beavo JA, Coleman RA, Bornfeldt KE. (2007) Rosiglitazone Inhibits Acyl-CoA Synthetase Activity and Fatty Acid Partitioning to Diacylglycerol and Triacylglycerol via a PPARγ-Independent Mechanism in Human Arterial Smooth Muscle Cells and Macrophages. Diabetes 56(4): 1143-1152
MacDougall ED, Kramer F, Polinsky P, Barnhart S, Askari B, Johansson F, Varon R, Rosenfeld ME, Oka K, Chan L, Schwartz SM, Bornfeldt KE. (2006) Aggressive Very Low-Density Lipoprotein (VLDL) and LDL Lowering by Gene Transfer of the VLDL Receptor Combined with a Low-Fat Diet Regimen Induces Regression and Reduces Macrophage Content in Advanced Atherosclerotic Lesions in LDL Receptor-Deficient Mice. American Journal of Pathology 168(6): 2064-2073
Renard CB, Askari B, Suzuki LA, Kramer F, Bornfeldt KE. (2003) Oleate, not Ligands of the Receptor for Advanced Glycation End-Products, Promotes Cell Cycle Progression in Human Arterial Smooth Muscle Cells. Diabetologia Dec; 46(12): 676-87
Askari B, Carroll MA, Capparelli M, Kramer F, Gerrity RG, Bornfeldt KE. (2002) Oleate and Linoleate Enhance the Growth Promoting Effects of IGF-I through a Phospholipase D-dependent Pathway in Porcine Smooth Muscle Cells. Journal of Biological Chemistry 277(39): 363**-*****
Askari B, Ferreri NR. (2001) Regulation of Prostacyclin Synthesis by Angiotensin II and TNF-α in Vascular Smooth Muscle. Prostaglandins and Other Lipid Mediators 63(4): 175-187
Askari B, Bell-Quilley CP, Fulton DR, Quilley J, McGiff JC. (1997) Analysis of Eicosanoid Mediation of the Functional Effects of Hyperchloremia in the Rat Isolated Kidney. Journal of Pharmacology and Experimental Therapeutics 282(1): 101-107
Ferreri NR, Millet I, Askari B, Magnani P, Ruddle NH. (1997) Lymphotoxin-β and TNF Regulation in T Cell Subsets: Differential Effects of PGE2. Cytokine 9(3): 157-165
Johnson RA, Lavesa M, Askari B, Abraham NG, Nasjletti A. (1995) A Heme Oxygenase Product, Presumably Carbon Monoxide, Mediates a Vasodepressor Function in Rats. Hypertension 25(2): 166-169
Ferreri NR, Askari B, Mahboubi K, Ruddle NH. (1993) Tumor Necrosis Factor-α and Lymphotoxin: Regulation by PGE2 in T-Cell Subsets. Immunomethods (2): 245-254
INVITED REVIEWS:
Askari B, Renard CB, Bornfeldt KE. (2002) Regulation of Smooth Muscle Cell Accumulation in Diabetes-accelerated Atherosclerosis. Histology and Histopathology (Cellular and Molecular Biology) 17(4): 1317-1328
REFERENCES:
Charles E. Alpers, M.D. Phone: 206-***-****
Professor and Vice Chairman Fax: 206-***-****
Department of Pathology
University of Washington School of Medicine
1959 NE Pacific St.
Box 357470
Seattle, WA 98195
Email: k8x6wr@r.postjobfree.com
Kevin D. O'Brien, M.D. Phone: 206-***-****
Professor of Medicine Fax:206-***-****
University of Washington School of Medicine
Seattle, WA 98195-6422
Email: k8x6wr@r.postjobfree.com
Karin E. Bornfeldt, Ph.D. Phone: 206-***-****
Associate Director, The Diabetes and Obesity Center of Excellence Fax: 206-***-****
Professor, Department of Pathology
Box 358050
815 Mercer Street
University of Washington School of Medicine
Seattle, WA 98109
Email: k8x6wr@r.postjobfree.com
John C. McGiff, M.D. Phone: 914-***-****
Professor Emeritus Fax: 914-***-****
Department of Pharmacology
Basic Sciences Building
New York Medical College
Valhalla, NY 10595
Email: k8x6wr@r.postjobfree.com